Clicky

Agenus Inc.(AGEN)

Description: Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Alzheimer's Disease Vaccines Vaccination Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Carcinoma Shingles Malaria Renal Cell Carcinoma Cancer Vaccine Herpes Glioma Metastatic Melanoma Experimental Cancer Treatments Herpes Simplex Research Genital Herpes Agenus Oncophage

Home Page: www.agenusbio.com

AGEN Technical Analysis

3 Forbes Road
Lexington, MA 02421-7305
United States
Phone: 781 674 4400


Officers

Name Title
Dr. Garo H. Armen Ph.D. Founder, Exec. Chairman & CEO
Ms. Christine M. Klaskin VP of Fin., Principal Financial Officer & Principal Accounting Officer
Dr. Steven J. O'Day M.D., Ph.D. Chief Medical Officer
Dr. Jennifer S. Buell Ph.D. Pres & CEO of MiNK Therapeutics
Craig Winter Chief Information Officer
Regina Grebla Ph.D. VP of Investor Relations & Communications
Ms. Robin E. Abrams J.D. Chief Legal Officer
Ms. Tracy Mazza Clemente Chief People Officer
John Castle Head of Translational Medicine & Bioinformatics
Ms. Julie DeSander Chief Bus. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 9.48
Price-to-Book MRQ: 218.6149
Price-to-Sales TTM: 8.2731
IPO Date: 2000-02-04
Fiscal Year End: December
Full Time Employees: 441
Back to stocks